Background: Endoglycosidic heparanase degrades heparan sulfate glycosaminoglycans, and may be important in cancer invasion and metastasis, although its expression in human cervical cancer has not been characterized.
Introduction
Owing to the availability of cervical cytology screening programs, the incidence of invasive cervical cancer is decreasing. Nevertheless, invasive cervical cancer remains a major health concern throughout the world. Tumor cell invasion and subsequent metastasis via blood and lymph vessels are critical steps in malignant tumor progression, including cervical cancer.
Heparan sulfate proteoglycans (HSPG), in which heparan sulfate glycosaminoglycans (HS-GAG) chains are covalently attached, are classified into several families according to the amino acid sequence of the core protein, such as syndecans and perlecan [1, 2] . Syndecans, cell surface HSPG, participate in cellcell and cell-extracellular matrix (ECM) interactions [1, 3] . Syndecan-1 is the most studied member of the syndecan family. Decreased expression of syndecan-1 has been reported to correlate with tumorigenicity, tumor invasion and progression [4] [5] [6] . In fact, decreased expression of syndecan-1 has been reported in invasive cervical cancers [7] . Syndecan-1 binds to various ECM components, such as collagen and fibronectin, via its HS-GAG, and most of its biological functions are considered to be associated with this process [1] [2] [3] . On the other hand, perlecan, a basement membrane-bound HSPG, is one of the main components of the basement membrane. In carcinomas, basement membranes often separate tumor cells from the surrounding tissue, and represent the main barrier limiting tumor invasion [8] . Furthermore, the penetration of the basement membranes in blood or lymphatic vessels is an essential step in the process of metastasis [9] .
Endoglycosidic heparanase, which cleaves HS-GAG at only a few sites, degrades HS-GAG into fragments of appreciable size [10] . The cDNA sequence of the heparanase gene was recently reported, and its mRNA found to be preferentially expressed in various human tumor tissues, including cervical cancer [11] [12] [13] . Heparanase activity has been shown to correlate with the metastatic potential of mouse melanoma and lymphoma cell lines [14, 15] . Furthermore, heparanase may contribute to angiogenesis by releasing HSPG-binding angiogenic factors [16] .
Heparanase may be important in cancer invasion and metastasis, although its expression in human cervical cancer has not previously been characterized. Therefore, we investigated the expression of heparanase mRNA in 10 normal cervix, five microinvasive and 87 invasive cervical cancer specimens using semi-quantitative RT-PCR. Moreover, the association between heparanase mRNA expression and clinicopathological features including microvessel counts and patient prognosis was determined.
Materials and methods

Patients and tissue samples
The patient population consisted of 92 individuals presenting with microinvasive or invasive cervical cancer (Department of Obstetrics and Gynecology of Okayama University Medical School, Okayama, Japan). Informed consent was obtained from all patients. Biopsy specimens were obtained prior to the initiation of treatment. Each specimen was partitioned into two equal portions. One sample was snap-frozen and stored at -80°C until required for RNA extraction. The second sample was fixed in 10% formaldehyde solution for histopathological examination. Specimens that did not contain significant cancer cells by histopathological diagnosis were excluded from the study.
Histological cell types of tumors were assigned according to the World Health Organization (WHO) classification: 58 were classified as squamous cell carcinoma, 22 as adenocarcinoma and 12 as adenosquamous carcinoma. Staging was reviewed based on the International Federation of Gynecology and Obstetrics (FIGO) staging system: five, 27, 44, 12 and four were categorized as stage IA1, IB, II, III and IV, respectively. The median age at the time of treatment was 50 years (range 26-90). Radical hysterectomy and pelvic lymphadenectomy were performed on 64 subjects with stage IB-IIB disease but otherwise in good physical condition. Patients displaying lymph node metastasis, parametrial involvement, deep stromal invasion or marked lymph-vascular space involvement were treated with adjuvant external whole-pelvic irradiation (50 Gy) or adjuvant combination chemotherapy. Total abdominal hysterectomy was performed on five subjects with stage IA1 disease. The remaining 23 patients were treated primarily with radiotherapy or concurrent chemoradiotherapy. Disease-free and overall survival were defined as the interval from the initial therapy to clinically or radiologically proven recurrence and death, respectively. The end of the follow-up study for analysis was 31 March 2002. The median duration of follow-up was 36 months (range 3-83). In addition, 10 normal cervical specimens were obtained from patients exhibiting benign gynecological disease.
RNA preparation of samples and RT-PCR
Total RNA was prepared from each specimen using an RNeasy Total RNA kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. Tissues exhibiting RNA characterized by high quality 18S and 28S bands on ethidium bromide-stained gels were preferentially selected.
Reverse transcription was conducted according to the Thermoscript RT-PCR System (Life Technologies, Rockville, MD, USA) protocol for reverse transcription of 3 µg total RNA. Transcribed products were subjected to PCR for heparanase (sense primer, 5′-TTCGATCCCAAGAAGGAATCAAC-3′; antisense primer, 5′-GTAGTGATGCCATGTAACTGAATC-3′) [13] and β-actin (sense primer, 5′-CTCACCATGGATGATGATAT-3′; antisense primer, 5′-TGGGTCATCTTCTCGCGGTT-3′) in a PCR mixture described elsewhere [17] . Heparanase cDNA amplification was initiated with denaturation for 3 min at 94°C followed by 30 cycles of 1 min denaturation at 94°C, annealing at 60°C for 1 min, followed by extension at 72°C for 1 min. The PCR profile for β-actin consisted of an initial denaturation of 3 min at 94°C, followed by 30 cycles of 1 min denaturation at 94°C, 1 min annealing at 55°C and a 1 min extension at 72°C. The PCR mixture was maintained at 72°C for 15 min for final extension. Resultant PCR products were then electrophoresed through a 2% agarose gel and stained with ethidium bromide. UV-illuminated gels were photographed using Polaroid Type 667 films. Photographs were quantitated using an image scanner GT-9500 (Epson, Suwa, Japan) and analyzed with Basic Quantifier software (BioImage, Ann Arbor, MI, USA).
In order to obtain semi-quantification of heparanase mRNA levels, cDNA amounts were corrected using β-actin as the internal standard. For this reason, a technique based on the competitive PCR approach employing a non-homologous internal standard was utilized (COMPETITOR, Competitive DNA Construction Kit; Takara, Kyoto, Japan). cDNAs derived from samples were co-amplified in the presence of serial dilutions of β-actin COMPETITOR. The point of equal intensity between the bands of β-actin COMPETITOR and the cDNA template was then determined. cDNAs in the presence of 1 × 10 4 copies of β-actin were subsequently used in the amplification of heparanase genes. PCR products derived from heparanase genes were assigned to strongly positive (2+), positive (+), or weak or negative (-) heparanase expressing groups according to band intensity.
Immunohistochemical staining for microvessels
Expression of factor VIII-related antigen was assessed in 64 formalin-fixed, paraffin-embedded sections obtained at the time of radical surgery by the avidin-biotin complex (ABC) procedure. Anti-factor VIII-related monoclonal antibody (Dakopatts, Copenhagen, Denmark) was utilized as a primary antibody. The entire tumorous lesion was scanned under low-power magnification in order to select regions displaying the most intense vascularization. The number of microvessels was recorded by counting any positively stained endothelial cell or endothelial cell clusters as a single, countable microvessel in a 100× microscopic field (0.618 mm 2 ) in 10 neovascularized areas. The mean of the top three counts was used as the microvessel count for each case.
Statistical analyses
Univariate analysis included the χ 2 -test, Spearman rank correlation test and Mann-Whitney U-test. Survival rates were calculated by the Kaplan-Meier method and differences were examined by the log-rank test. Furthermore, the prognostic factors for disease-free and overall survival were determined by stepwise Cox's univariate and multivariate proportional hazard models. These analyses were performed utilizing the StatView v. 5.0 software (Abacus Concepts, Berkeley, CA, USA). P values <0.05 were considered statistically significant.
Results
Expression of heparanase mRNA in normal cervix and invasive cervical cancer (lane 2), normal cervix (lanes 3-5), microinvasive (lane 6 and 7) and invasive (lanes 8-12) cervical cancer. Expression of heparanase mRNA was not detected in any of the normal cervix specimens. Heparanase mRNA expression was significantly higher in advanced-stage tumors (P = 0.026) ( Table 1) . No meaningful differences in heparanase mRNA expression were observed with respect to age and histological cell type. In cases treated with radical hysterectomy and pelvic lymphadenectomy, heparanase mRNA expression was significantly higher in tumors exhibiting lymphvascular space invasion (P = 0.01) ( Table 2) . No correlation was found between heparanase mRNA expression and other clinicopathological factors. We also examined the correlation between heparanase mRNA expression and microvessel counts. Figure 2 showes that heparanase gene expression is correlated with tumor vascularity in invasive cervical cancer. Figure 3 presents the disease-free and overall survival curves of the 87 patients displaying invasive cervical cancer according to the heparanase mRNA expression status. The disease-free and overall survival rates of patients exhibiting heparanase mRNA expression were significantly lower than those of patients lacking heparanase mRNA expression (P = 0.019 and 0.017, respectively). Furthermore, multivariate analysis showed that heparanase mRNA expression was an independent prognostic factor for both disease-free and overall survival (Tables 3 and 4) . Patient diseasefree survival in the 64 cases of cervical cancer treated with radical hysterectomy and pelvic lymphadenectomy was poorer in instances characterized by the presence of heparanase mRNA expression. However, this finding was not statistically significant (data not shown).
Association of heparanase mRNA expression with survival
Discussion
In the current study, heparanase mRNA expression in normal cervix and invasive cervical cancer specimens was investigated. The catalytic activities and mRNA levels of heparanase have been demonstrated to be correlated [18] . We found no heparanase mRNA in normal cervix, which is consistent with the result that the expression of heparanase mRNA in normal tissues is restricted to cytotrophoblasts, endothelial cells, keratinocytes, platelets, mast cells, neutrophils, macrophages, and T and B lymphocytes [19] . Via HS-GAG attached to the extracellular domain, syndecan-1 binds many ECM molecules and plays a role as a matrix anchor. Reduced tumor cell adhesion is prerequisite for invasion and metastasis. In fact, decreased expression of syndecan-1 has been reported in invasive cervical cancers [6] . Mikami et al. [20] reported that a reduction in HS-GAG expression was more pronounced than that of core protein in invasive esophageal carcinomas.
These findings suggest that cleavage of HS-GAG from syndecan-1 core protein, which is mediated by heparanase, is very important for reduced tumor cell adhesion and accelerated tumor cell invasion. In the present study, we demonstrated that heparanase mRNA expression is significantly higher in invasive cervical cancer at the advanced stage. All cases with distant metastasis expressed heparanase mRNA, whereas this mRNA was not detectable in the cases with microinvasive cancer. The present data are compatible with the reports of positive correlation between heparanase expression and tumor progression in cases of bladder, colon, pancreatic, hepatocellular, oral, gastric and esophageal cancers [18, [20] [21] [22] [23] [24] [25] . These findings suggest that heparanase expression may contribute to the progression of malignant solid tumors. Furthermore, we demonstrated that heparanase mRNA expression is significantly higher in cases where lymph-vascular space involvement was in evidence. Mikami et al. [20] reported that heparanase expression correlates with the incidence of lymphatic invasion and venous involvement in invasive esophageal carcinomas. Tang et al. [25] reported that heparanase expression correlates with lymphatic and venous invasion in gastric carcinomas. In addition, intense heparanase immunostaining was observed in breast carcinoma cells that had entered the circulation, and in lymph node metastases [26] . HSPG are found in the subendothelial basement membrane of capillaries [27] . Therefore, cleavage of HSPG may enable tumor cells to invade through blood vessel walls.
In addition, heparanase may contribute to angiogenesis by releasing HSPG-binding angiogenic factors, such as basic fibroblast growth factors, vascular endothelial growth factor (VEGF), platelet-derived endothelial growth factor, interleukin-8, hepatocyte growth factor and transforming growth factor-β [16] . In a previous study, we showed that the expression of VEGF is involved in the promotion of angiogenesis in cervical cancer [28] . We also demonstrated in the present study that heparanase gene expression correlates with tumor vascularity in invasive cervical cancer. In accordance with this, heparanase expression has been reported to be correlated with increased microvessel counts in bladder and esophageal cancers [20, 21] .
Heparanase mRNA expression was examined to the correlation with prognosis in invasive cervical cancer. Heparanase is a significant prognostic factor in bladder, pancreatic and gastric cancers [21, 23, 25] , which is consistent with the present study regarding the association of heparanase mRNA expression with poor prognosis. Furthermore, heparanase mRNA was an independent prognostic factor both in progression-free and overall survival in the present study. Thus, heparanase expression will most likely be a useful prognostic factor in patients presenting with invasive cervical cancer. However, a study involving a large cohort of patients is required to confirm this possibility.
Sulfated polysaccharides such as heparin, dextran sulfate and xylan sulfate are very effective inhibitors of tumor metastasis, although it was originally thought that the antimetastatic properties of these compounds were due to their anticoagulant activity. Recent studies have revealed that the antimetastatic activity of the sulfated polysaccharides correlates with their ability to inhibit the enzyme heparanase rather than their potency as anticoagulants [29] . Although the existence of a heparanase inhibitor has been found in murine melanoma cells, an inhibitor molecule has not yet been isolated [30] . Heparanase inhibitor may be an important strategy for antimetastatic drugs in invasive cervical cancer.
In conclusion, our findings provide evidence that heparanase expression can serve as an indicator representing aggressive potential and poor prognosis in cervical cancer. Heparanase inhibitor will be a novel candidate for therapeutic intervention in this disease.
